Tositumomab and iodine [1311] tositumomab in the management of follicular lymphoma. An oncologist's view
Tositumomab and iodine [1311] tositumomab in the management of follicular lymphoma. An oncologist's view
Iodine [131I] tositumomab, administered in combination with unlabelled tositumomab, is a novel radioimmunotherapeutic regimen that targets the CD20 antigen present on normal and malignant B-cells. The efficacy and safety of the non-myeloablative regimen has been demonstrated in follicular and transformed follicular lymphoma over the last decade in a series of clinical studies, culminating in FDA approval in June 2003. In patients with relapsed or refractory disease some remissions have proven to be durable, and frequently longer in duration than previously administered chemotherapeutic agents. As initial therapy for advanced stage follicular lymphoma, response rates are particularly impressive. Toxicity has been principally haematological, with a single nadir at 4-6 weeks post-therapy. Administration is free of many of the side effects of conventional chemotherapy, although concerns about the long term risk of therapy related myelodysplasia persist. The challenge now comes from deciding the correct place of iodine [131I] tositumomab in treatment algorithms for follicular and other ‘indolent’ lymphomas. Sequential administration after chemotherapy is being actively investigated, as is its role in myeloablative therapy. Issues of cost-benefit aside, it is a significant development in the therapy of these ‘chronic’ malignancies.
305-316
Davies, A.J.
0fe6a40a-10d1-4ade-a7e6-d1dceb2470af
December 2004
Davies, A.J.
0fe6a40a-10d1-4ade-a7e6-d1dceb2470af
Davies, A.J.
(2004)
Tositumomab and iodine [1311] tositumomab in the management of follicular lymphoma. An oncologist's view.
The Quarterly Journal of Nuclear Medicine and Molecular Imaging, 48 (4), .
Abstract
Iodine [131I] tositumomab, administered in combination with unlabelled tositumomab, is a novel radioimmunotherapeutic regimen that targets the CD20 antigen present on normal and malignant B-cells. The efficacy and safety of the non-myeloablative regimen has been demonstrated in follicular and transformed follicular lymphoma over the last decade in a series of clinical studies, culminating in FDA approval in June 2003. In patients with relapsed or refractory disease some remissions have proven to be durable, and frequently longer in duration than previously administered chemotherapeutic agents. As initial therapy for advanced stage follicular lymphoma, response rates are particularly impressive. Toxicity has been principally haematological, with a single nadir at 4-6 weeks post-therapy. Administration is free of many of the side effects of conventional chemotherapy, although concerns about the long term risk of therapy related myelodysplasia persist. The challenge now comes from deciding the correct place of iodine [131I] tositumomab in treatment algorithms for follicular and other ‘indolent’ lymphomas. Sequential administration after chemotherapy is being actively investigated, as is its role in myeloablative therapy. Issues of cost-benefit aside, it is a significant development in the therapy of these ‘chronic’ malignancies.
This record has no associated files available for download.
More information
Published date: December 2004
Identifiers
Local EPrints ID: 73337
URI: http://eprints.soton.ac.uk/id/eprint/73337
ISSN: 1824-4785
PURE UUID: b9c66d91-a05a-41d5-a947-7039cd1da604
Catalogue record
Date deposited: 11 Mar 2010
Last modified: 14 Mar 2024 02:54
Export record
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics
